Literature DB >> 23443941

Histopathological features of ductal adenocarcinoma of the prostate in 1,051 radical prostatectomy specimens.

Amanda H Seipel1, Fredrik Wiklund, N Peter Wiklund, Lars Egevad.   

Abstract

Ductal adenocarcinoma (DAC) of the prostate is thought to have worse prognosis than prostatic acinar carcinoma (PAC). We aimed to evaluate the prognostic significance of histopathological patterns of DAC. A series of 1,051 radical prostatectomy specimens from Karolinska University Hospital 1998-2005 was reviewed. A ductal component was classified as classical DAC (DACC) if it had columnar, pseudostratified epithelium, elongated nuclei, and papillary, glandular, or cribriform architecture; borderline DAC (DACB) if it lacked elongated nuclei or classical architecture; and prostatic adenocarcinoma with ductal features (PCDF) if stratified high-grade nuclei were found. DACC, DACB, and PCDF were seen in 2.6, 4.0, and 1.6 % of the cases. DAC was usually mixed with PAC and constituted 10-100 % (mean 40 %) of the main tumor. Location was periurethral, peripheral, or both in 69.8, 3.5, and 26.7 %. Necrosis was seen in 31.3 %, stromal invasion of DAC in 52.3 %, and intraductal spread in 91.9 %. In DACC/DACB and PAC, extraprostatic extension was seen in 66.7 and 42.4 % (p < 0.001) and seminal vesicle invasion in 13.0 and 5.0 % (p = 0.0045). DACC, DACB, and PCDF had a hazard ratio for biochemical recurrence of 1.5 (0.7-2.8), 1.4 (0.8-2.6) and 1.2 (0.5-2.7). When PCDF was excluded from DAC, hazard ratio was 1.4 (95 % CI 0.9-2.3, p = 0.12). Location, % DAC, necrosis, stromal invasion, or Gleason score were not predictive of recurrence. This suggests that DACC and DACB are more aggressive than average PAC, while cancers with acinar architecture and pseudostratified high-grade nuclei should not be included in DAC.

Entities:  

Mesh:

Year:  2013        PMID: 23443941     DOI: 10.1007/s00428-013-1385-5

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  24 in total

1.  Metastatic ductal adenocarcinoma of the prostate: cytologic features and clinical findings.

Authors:  Yun Gong; Nancy Caraway; John Stewart; Gregg Staerkel
Journal:  Am J Clin Pathol       Date:  2006-08       Impact factor: 2.493

2.  Endometrial carcinoma of proxtatic utricle (uterus masculinus).

Authors:  M M Melicow; M R Pachter
Journal:  Cancer       Date:  1967-10       Impact factor: 6.860

3.  Prostatic adenocarcinoma of ductal origin.

Authors:  V E Dube; G M Farrow; L F Greene
Journal:  Cancer       Date:  1973-08       Impact factor: 6.860

Review 4.  Prostatic ductal adenocarcinoma: a mini review.

Authors:  Jonathan I Epstein
Journal:  Med Princ Pract       Date:  2009-12-09       Impact factor: 1.927

5.  Prostatic duct adenocarcinoma. Findings at radical prostatectomy.

Authors:  W N Christensen; G Steinberg; P C Walsh; J I Epstein
Journal:  Cancer       Date:  1991-04-15       Impact factor: 6.860

6.  Ductal adenocarcinoma of the prostate: clinical features and implications after local therapy.

Authors:  Shi-Ming Tu; Adriana Lopez; Dan Leibovici; Mehmet A Bilen; Ferhat Evliyaoglu; Ana Aparicio; Charles C Guo; Deborah A Kuban; Marcy M Johnson; Louis L Pisters
Journal:  Cancer       Date:  2009-07-01       Impact factor: 6.860

7.  Adenocarcinoma of the prostate with endometrioid features. A light microscopic and immunohistochemical study of ten cases.

Authors:  J I Epstein; J M Woodruff
Journal:  Cancer       Date:  1986-01-01       Impact factor: 6.860

8.  Prostatic adenocarcinoma with endometrioid features. Clinical, pathologic, and ultrastructural findings.

Authors:  D G Bostwick; R W Kindrachuk; R V Rouse
Journal:  Am J Surg Pathol       Date:  1985-08       Impact factor: 6.394

9.  Role of radiotherapy in ductal (endometrioid) carcinoma of the prostate.

Authors:  Thomas N Eade; Tahseen Al-Saleem; Eric M Horwitz; Mark K Buyyounouski; David Y T Chen; Alan Pollack
Journal:  Cancer       Date:  2007-05-15       Impact factor: 6.860

10.  Papillary adenocarcinomas of the prostate. An immunohistochemical study.

Authors:  F P Kuhajda; T Gipson; G Mendelsohn
Journal:  Cancer       Date:  1984-10-01       Impact factor: 6.860

View more
  17 in total

1.  PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas.

Authors:  Carlos L Morais; Mehsati Herawi; Antoun Toubaji; Roula Albadine; Jessica Hicks; George J Netto; Angelo M De Marzo; Jonathan I Epstein; Tamara L Lotan
Journal:  Prostate       Date:  2015-07-14       Impact factor: 4.104

Review 2.  The update of prostatic ductal adenocarcinoma.

Authors:  Tantan Liu; Yingmei Wang; Ru Zhou; Haiyang Li; Hong Cheng; Jing Zhang
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

3.  Integrative Genomic Analysis of Coincident Cancer Foci Implicates CTNNB1 and PTEN Alterations in Ductal Prostate Cancer.

Authors:  Marc Gillard; Justin Lack; Andrea Pontier; Divya Gandla; David Hatcher; Adam G Sowalsky; Jose Rodriguez-Nieves; Donald Vander Griend; Gladell Paner; David VanderWeele
Journal:  Eur Urol Focus       Date:  2017-12-08

Review 4.  Cribriform Patterned Lesions in the Prostate Gland with Emphasis on Differential Diagnosis and Clinical Significance.

Authors:  Maria Destouni; Andreas C Lazaris; Vasiliki Tzelepi
Journal:  Cancers (Basel)       Date:  2022-06-21       Impact factor: 6.575

5.  Magnetic resonance imaging findings of pure prostatic ductal adenocarcinomas: a case series.

Authors:  Hiromi Edo; Yasuyo Urase; Yoshiko Ueno; Ayumu Kido; Tsutomu Tamada; Yudai Asano; Kentaro Ida; Hisataka Ito; Takashi Koyama; Kosuke Miyai; Hitoshi Tsuda; Hiroshi Shinmoto
Journal:  Abdom Radiol (NY)       Date:  2022-02-28

6.  Prostatic ductal adenocarcinoma: An aggressive variant that is underdiagnosed and undersampled on transrectal ultrasound (TRUS)-guided needle biopsy.

Authors:  Previn Gulavita; Shaheed W Hakim; Nicola Schieda; Rodney H Breau; Chris Morash; Daniel T Keefe; Susan J Robertson; Kien T Mai; Eric C Belanger; Trevor A Flood
Journal:  Can Urol Assoc J       Date:  2015 Sep-Oct       Impact factor: 1.862

Review 7.  Optimizing the diagnosis and management of ductal prostate cancer.

Authors:  Weranja Ranasinghe; Daniel D Shapiro; Miao Zhang; Tharakeswara Bathala; Nora Navone; Timothy C Thompson; Bradley Broom; Ana Aparicio; Shi-Ming Tu; Chad Tang; John W Davis; Louis Pisters; Brian F Chapin
Journal:  Nat Rev Urol       Date:  2021-04-06       Impact factor: 14.432

8.  ECR 2015 Book of Abstracts - D - Satellite Symposia.

Authors: 
Journal:  Insights Imaging       Date:  2015-03

9.  False positive and false negative diagnoses of prostate cancer at multi-parametric prostate MRI in active surveillance.

Authors:  Jeffrey S Quon; Bardia Moosavi; Maneesh Khanna; Trevor A Flood; Christopher S Lim; Nicola Schieda
Journal:  Insights Imaging       Date:  2015-05-23

10.  Clinicopathological features of prostate ductal carcinoma: matching analysis and comparison with prostate acinar carcinoma.

Authors:  Aram Kim; Taekmin Kwon; Dalsan You; In Gab Jeong; Heounjeong Go; Yong Mee Cho; Jun Hyuk Hong; Hanjong Ahn; Choung-Soo Kim
Journal:  J Korean Med Sci       Date:  2015-03-19       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.